Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with ...

Featuring Radha Agrawal, Charles Vogl, Dr. Iva Greywolf, and Dr. Robert Anda advancing dialogue on ACEs, community, and ...

Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the ...

With our Phase IIa program underway and defined milestones in front of us, we look forward to engaging with investors and potential partners at BIO.” — Christer Rosén, Chairman and Chief Executive ...

NeuroYogaNYC, a leader in integrating yoga with scientific research, is thrilled to announce its sixth annual Neuroscience and Yoga Conference, scheduled for March 19-22, 2026. This educational event ...

The MarketWatch News Department was not involved in the creation of this content. Featuring Keynote "Reuniting the Mind with the Heart" ATLANTA, Feb. 16, 2026 /PRNewswire/ -- The Atlanta Neuroscience ...

WASHINGTON, DC, UNITED STATES, January 5, 2026 / EINPresswire.com / — KeifeRx, a biopharmaceutical company developing oral, brain-penetrant kinase inhibitors for neurodegenerative diseases that ...

JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for ...

JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for … ...